supp.fit

Calcium and Vitamin D3: study protocols

30 study groups took Calcium together with Vitamin D3. These are the doses the studies gave. They are not a recommendation.

Calcium: what the research found →

Dose per serving from research: Calcium

29 study groups in 15 studies say how much Calcium participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 48% of 29 study groups.

Daily doseStudy groups
250 mg to 500 mg
5
500 mg to 1 g
14
1 g to 2.5 g
10

Dose per serving from research: Vitamin D3

22 study groups in 12 studies say how much Vitamin D3 participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 100 IU to 250 IU, 36% of 22 study groups.

Daily doseStudy groups
100 IU to 250 IU
8
250 IU to 500 IU
5
500 IU to 1,000 IU
7
1,000 IU to 2,500 IU
2

Commonly used together

13 of 30 study groups took Calcium and Vitamin D3 with something else, but nothing that 3 or more different studies gave.

30 study groups

Study
Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy
2024 · India trial, 500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation
500 mg250 IU——
Evaluation of efficacy of oral calcium phosphate as an adjunct to standard-of-care regular phototherapy in cases of neonatal jaundice: a hospital-based double-blind, randomised, placebo-controlled trial
2024 · intervention group · Neonates with neonatal jaundice requiring phototherapy, including term and preterm infants
75 mg/kg200 IU—40
Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy
2024 · India trial, 1500-mg group · Adults aged 18 years or older who were nulliparous and pregnant at less than 20 weeks’ gestation
1.5 g250 IU——
Acupuncture in Treating Osteopenia: A Multicenter, Randomized, Controlled Clinical Trial
2024 · acupuncture group · Patients with osteoporosis; age and sex not reported
600 mg—26 weeks116
Acupuncture in Treating Osteopenia: A Multicenter, Randomized, Controlled Clinical Trial
2024 · control group · Patients with osteoporosis; age and sex not reported
600 mg—26 weeks110
The Effect of the Modified Eighth Section of Eight-Section Brocade on Osteoporosis in Postmenopausal Women: A Prospective Randomized Trial
2015 · Ca alone · Postmenopausal women aged 50–75 with inadequate bone mass or osteoporosis
1.5 g600 IU1 year50
The Effect of the Modified Eighth Section of Eight-Section Brocade on Osteoporosis in Postmenopausal Women: A Prospective Randomized Trial
2015 · MESE + Ca · Postmenopausal women aged 50–75 with inadequate bone mass or osteoporosis
1.5 g600 IU1 year50
Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
2018 · PTH group · Postmenopausal women aged 45–80 with osteoporosis
1.25 g200 IU48 weeks43
Effect of two forms of alendronate administration upon bone mass after two years of treatment
2002 · Group I · Women with postmenopausal osteoporosis
1.2 g800 IU2 years40
Effect of two forms of alendronate administration upon bone mass after two years of treatment
2002 · Group II · Women with postmenopausal osteoporosis
1.2 g800 IU2 years40
Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
2018 · Alendronate (ALN) group · Postmenopausal women aged 45–80 with osteoporosis
1.25 g200 IU48 weeks22
The joint effect of energy reduction with calcium supplementation on the risk factors of type 2 diabetes in the overweight population: a two-year randomized controlled trial
2021 · energy-reduction with calcium supplementation group (ER-CSG) · Overweight adults aged 20–70 with low dietary calcium intake and no major disease; received dietary energy-reduction education as well as supplements
400 mg—2 years300
The joint effect of energy reduction with calcium supplementation on the risk factors of type 2 diabetes in the overweight population: a two-year randomized controlled trial
2021 · calcium supplementation group (CSG) · Overweight adults aged 20–70 with low dietary calcium intake and no major disease
400 mg—2 years298
The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
2024 · Intervention group · Adults aged 58–71 with type 2 diabetes and osteoporosis
600 mg—26 weeks50
The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
2024 · Control group · Adults aged 59–72 with type 2 diabetes and osteoporosis
600 mg—26 weeks49
One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans
2015 · Vitamin D3 plus calcium carbonate · Older German adults, mean age 67 years
456 mg1,200 IU1 year—
One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans
2015 · B-vitamin supplementation · Older German adults, mean age 67 years
456 mg1,200 IU1 year—
Plasma levels of adrenaline, noradrenaline, dopamine, serotonin, and cortisol in sarcopenia: comparison with non-sarcopenic individuals and the impact of resistance exercise and nutrition interventions
2025 · Combined exercise and nutritional intervention (sarcopenic participants; early versus delayed intervention trial) · Adults older than 65 years with sarcopenia
600 mg800 IU12 weeks57
Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women
2013 · potassium citrate 60 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause.
630 mg—26 weeks17
Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women
2013 · potassium citrate 90 mmol/day · Healthy men and women older than 55 years, with 24-hour urine calcium at or above the study threshold; women were more than five years past menopause.
630 mg—26 weeks17
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease
2013 · Calcium carbonate · Men and women aged 35 years or older with stage 3–4 chronic kidney disease, GFR <45 mL/min, and serum PTH at least the mid-normal range; all analyzed participants were overweight and had hypertension
1.5 g400 IU3 weeks8
Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial
2015 · Low-dose KHCO3 group · Healthy ambulatory men and postmenopausal women aged 60 years and older
600 mg500 IU12 weeks—
Potassium Bicarbonate Supplementation Lowers Bone Turnover and Calcium Excretion in Older Men and Women: A Randomized Dose-Finding Trial
2015 · High-dose KHCO3 group · Healthy ambulatory men and postmenopausal women aged 60 years and older
600 mg500 IU12 weeks—
Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention
2023 · Early intervention group · Adults aged 65 years and older with sarcopenia
600 mg800 IU12 weeks—
Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention
2023 · Delayed intervention group · Adults aged 65 years and older with sarcopenia
600 mg800 IU12 weeks—
Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants
2009 · cinacalcet group · Healthy men and postmenopausal women aged 45–70 years
1.2 g400 IU11 days9
Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participants
2009 · placebo group · Healthy men and postmenopausal women aged 45–70 years
1.2 g400 IU11 days8
Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women
2015 · Caloric restriction-only group (CR) · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²)
1 g200 IU20 weeks—
Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women
2015 · Moderate-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²)
1 g200 IU20 weeks—
Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women
2015 · Vigorous-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²)
1 g200 IU20 weeks—